ReviewFrontiers in immunology2021

Integrin-α9β1 as a Novel Therapeutic Target for Refractory Diseases: Recent Progress and Insights.

Shihan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.